Anthony Altig Net Worth

Anthony Altig biography

Anthony E. Altig serves as Independent Director of the Company. Mr. Altig joined our Board in January 2012. From 2008 to December 2017, Mr. Altig was the Chief Financial Officer of Biotix Holdings, Inc., a company that manufactures microbiological consumables, which was acquired by Mettler Toledo in September 2017. From 2004 to 2007, Mr. Altig served as the Chief Financial Officer of Diversa Corporation (subsequently Verenium Corporation), a public company developing specialized industrial enzymes. Prior to joining Diversa, Mr. Altig served as the Chief Financial Officer of Maxim Pharmaceuticals, Inc., a public biopharmaceutical company. In addition, Mr. Altig serves as a director and chairman of the audit committee for TearLab Corporation (formerly OccuLogix, Inc.), a publicly traded eyecare technology company. He formerly served as a director of MultiCell Technologies, Inc. and Optimer Pharmaceuticals, Inc., a pharmaceutical company, which was a public company until its acquisition by Cubist Pharmaceuticals, Inc. in October 2013. Mr. Altig received his B.B.A. in business from the University of Hawaii at Manoa and is a Certified Public Accountant (inactive).

What is the salary of Anthony Altig?

As the Independent Director of Assembly Biosciences Inc, the total compensation of Anthony Altig at Assembly Biosciences Inc is $169,082. There are 10 executives at Assembly Biosciences Inc getting paid more, with John McHutchison having the highest compensation of $7,007,210.

How old is Anthony Altig?

Anthony Altig is 64, he's been the Independent Director of Assembly Biosciences Inc since 2012. There are 5 older and 12 younger executives at Assembly Biosciences Inc. The oldest executive at Assembly Biosciences Inc is Alan Lewis, 74, who is the Independent Director.

What's Anthony Altig's mailing address?

Anthony's mailing address filed with the SEC is C/O ASSEMBLY BIOSCIENCES, INC., TWO TOWER PLACE, 7TH FLOOR, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Assembly Biosciences Inc

Over the last 10 years, insiders at Assembly Biosciences Inc have traded over $1,523,622 worth of Assembly Biosciences Inc stock and bought 1,245,980 units worth $1,060,065 . The most active insiders traders include Sciences, Inc. Gilead, Myron Z Holubiak, eHelen Susan Kim. On average, Assembly Biosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of $389,399. The most recent stock trade was executed by Nicole S White on 2 August 2024, trading 785 units of ASMB stock currently worth $11,171.

What does Assembly Biosciences Inc do?

assembly biosciences, inc. (nasdaq: asmb) is a public clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and novel oral live biotherapeutics for disorders associated with the microbiome. assembly is developing two innovative platform programs: an hbv program advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and a microbiome program developing novel oral live biotherapeutics designed to address diseases associated with the microbiome. assembly’s hbv program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic hbv. the company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current good manufacturing practices and a patent-pending delivery system, gemicel®, which allows for targeted ora

Assembly Biosciences Inc executives and stock owners

Assembly Biosciences Inc executives and other stock owners filed with the SEC include:

• John McHutchison,
  President, Chief Executive Officer, Director
• Jacqueline Papkoff,
  Senior Vice President, Chief Scientific Officer Microbiome
• Thomas Joseph Russo,
  Chief Financial Officer
• Luisa Stamm,
  Chief Medical Officer
• Dr. John G. McHutchison A.O., FRACP, M.D.,
  CEO, Pres & Director
• Jason A. Okazaki,
  Chief Operating Officer
• Dr. William E. Delaney IV, Ph.D.,
  Chief Scientific Officer
• William Ringo,
  Non-Executive Independent Chairman of the Board
• Myron Holubiak,
  Independent Director
• Alan Lewis,
  Independent Director
• Anthony Altig,
  Independent Director
• Susan Mahony,
  Independent Director
• Richard DiMarchi,
  Independent Director
• Helen Kim,
  Independent Director
• Nicole White,
  Senior Vice President - Pharmaceutical Development and Manufacturing
• Gina Consylman,
  Independent Director
• Jason Okazaki,
  Chief Legal and Business Officer
• William Delaney,
  Chief Scientific Officer - Virology
• Steven Knox,
  Senior Vice President - Clinical Development
• David Houck,
  Senior Vice President - Product Development and Portfolio Management
• Michele Anderson,
  Chief Devel. Officer
• Dr. Tharaknath Rao,
  Head of Microbiome Clinical Devel. & Sr. VP
• Dr. Richard J. Colonno,
  Sr. Advisor
• Jennifer A. Troia MHROD, SHRM-SCP, SPHR,
  Chief HR Officer
• Lauren Glaser,
  Sr. VP of Investor Relations & Corp. Affairs
• Michael P. Samar,
  CFO & Principal Accounting Officer
• Dr. Adam Zlotnick,
  Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory Board
• Dr. Uri A. Lopatin M.D.,
  Co-Founder and Clinical & Scientific Advisor
• Graham K Cooper,
  See Remarks
• Mark Auerbach,
  Director
• David Jonathan Barrett,
  See Remarks
• Thomas E Rollins,
  Chief Development Officer
• Uri A Lopatin,
  Chief Medical Officer
• Michael Houghton,
  
• Derek A Small,
  Director
• Richard James Colonno,
  EVP & CSO, Virology Ops
• Capital Fund Qualified, L.P...,
  10% owner
• Lisa Johnson Pratt,
  
• Anuj Gaggar,
  Chief Medical Officer
• Adam Zlotnick,
  10% owner
• Sciences, Inc. Gilead,
  10% owner
• Michael P. Samar,
  Chief Financial Officer
• Jeanette M Bjorkquist,
  Principal Accounting Officer
• Alexander Schornstein,
  10% owner